Use of thiophoshonoformic acid and nrtis to treat viral infections
AssigneeAdventrix Pharmaceuticals, Inc.
InventorsShani Waninger, Joan Robbins, Ramos Silvestri
Life of this patent
Estimating the term…
Abstract
This invention provides for a method of synergistically reducing viral load in a patient infected with a virus. The method comprises the oral co-administering an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor in a synergistic combination.
Claims22
A method of reducing viral load in a patient infected with a virus, the method comprising the oral co-administering to the patient of an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor where the amounts being co-administered are sufficient to synergistically lower the viral load and where the thiophosphonoformic acid is orally administered in a dosage range of between 2 mg/kg to 50 mg/kg per day.
An oral medicament for lowering viral load in a patient infected with a virus, where the medicament is a combined formulation comprising an amount of thiophosphonoformic acid and an amount of a nucleoside or nucleotide reverse transcriptase inhibitor where the thiophosphonoformic acid and nucleoside or nucleotide reverse transcriptase inhibitor are present in amounts sufficient to synergistically lower viral load and the medicament contains between 150 mg and 750 mg of thiophosphonoformic acid per combined formulation.
The use of thiophosphonoformic acid and a nucleoside or nucleotide reverse transcriptase inhibitor in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a viral infection where the thiophosphonoformic acid and nucleoside or nucleotide reverse transcriptase inhibitor are present in amounts sufficient to synergistically lower viral load and the medicament contains between 150 mg and 750 mg of thiophosphonoformic acid per combined formulation.
The use of thiophosphonoformic acid and a nucleoside or nucleotide reverse transcriptase inhibitor in the preparation of an anti-viral agent in ready-to-use drug form for treating or preventing virus infections where the where the thiophosphonoformic acid and nucleoside or nucleotide reverse transcriptase inhibitor are present in amounts sufficient to synergistically lower viral load and the ready-to-use drug form contains less than 500 mg of thiophosphonoformic acid per form.
Dependencies are inferred from the claim text.